title: Extreme hyperbilirubinaemia in term and near-term infants in Denmark.
abstract: OBJECTIVE
  To determine the incidence amongst infants born at term or near-term of extreme hyperbilirubinaemia, i.e., with a serum concentration of unconjugated bilirubin exceeding the limit above which an exchange transfusion was indicated according to the authorized guidelines.
  
  
  METHODS
  The investigation period covered 2 y, 1 January 2000 to 31 December 2001, and included all infants born alive at term or near-term in Denmark. All infants with extreme hyperbilirubinaemia admitted to paediatric departments were recorded.
  
  
  RESULTS
  Thirty-two infants developed extreme hyperbilirubinaemia, i.e., an incidence of 25 per 100 000. The maximum total serum bilirubin concentration (TSB) was 492 (385-689) micromol/I (median (range)). The median value of the exchange transfusion limits was 450 micromol/l. Twelve infants had signs and symptoms of central nervous system involvement; 11 had acute bilirubin encephalopathy phase-1 symptoms; and one had phase-2 symptoms. Nineteen infants developed extreme hyperbilirubinaemia during primary admission to the maternity ward or neonatal department; the others after having been discharged. There was no difference in maximum TSB between those infants not discharged from hospital and those infants admitted to hospital from home. Maximum TSB appeared latest amongst those infants admitted from home (p < 0.01), and these more often had signs and symptoms of central nervous system involvement (p < 0.05). Ten infants were of non-Caucasian extraction. Less than half of all Danish mothers receive both verbal and written information after birth on jaundice in the infant.
  
  
  CONCLUSIONS
  Twenty-five per 100 000 infants born at term or near-term developed extreme hyperbilirubinaemia, the majority of them whilst in hospital. Infants admitted from home more often had signs and symptoms of central system involvement.
authors.affiliation: Department of Paediatrics, Aalborg University Hospital, Denmark. u19091@aas.nja.dk
authors.forename: F
authors.initials: F
authors.lastname: Ebbesen
authors.forename: C
authors.initials: C
authors.lastname: Andersson
authors.forename: H
authors.initials: H
authors.lastname: Verder
authors.forename: C
authors.initials: C
authors.lastname: Grytter
authors.forename: L
authors.initials: L
authors.lastname: Pedersen-Bjergaard
authors.forename: J R
authors.initials: JR
authors.lastname: Petersen
authors.forename: J
authors.initials: J
authors.lastname: Schaarup
mesh_terms: D001663:Bilirubin / Q000097:blood; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005865:Gestational Age; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000453:epidemiology* / Q000517:prevention & control; D007567:Jaundice, Neonatal / Q000150:complications / Q000453:epidemiology* / Q000517:prevention & control; D007647:Kernicterus / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D008297:Male; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D001663:Bilirubin